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Abstract
Background: To evaluate the midterm results of patients with angina and diffuse coronary artery disease treated
with transmyocardial revascularization in combination with autologous stem cell therapy.
Methods: Nineteen patients with diffuse coronary artery disease and medically refractory class III/IV angina were
evaluated between June 2007 and December 2009 for sole therapy TMR combined with intramyocardial injection
of concentrated stem cells. At the time of surgery, autologous bone marrow (120cc) was aspirated from the iliac
crest. A cardiac MRI and an isotopic test were performed before and after the procedure. Follow-up was performed
by personal interview.
Results: There were no perioperative adverse events including no arrhythmias. Mean number of laser channels
was 20 and the mean total number of intramyocardially injected cells per milliliter were: total mononuclear cells
(83.6 × 10
6), CD34+ cells(0.6 × 10
6), and CD133+ cells(0.34 × 10
6). At 12 months mean follow-up average angina
class was significantly improved (3.4 ± 0.5 vs 1.4 ± 0.6; p = 0.004). In addition, monthly cardiovascular medication
usage was significantly decreased (348 ± 118 vs. 201 ± 92; p = 0.001). At six months follow up there was a
reduction in the number of cardiac hospital readmissions (2.9 ± 2.3 vs. 0.5 ± 0.8; p < 0.001). MRI showed no
alterations regarding LV volumes and a 3% improvement regarding ejection fraction.
Conclusions: The stem cell isolator efficiently concentrated autologous bone marrow derived stem cells while the
TMR/stem cell combination delivery device worked uneventfully. An improvement in clinical status was noticed in
the midterm follow-up. Images test showed no morphological alterations in the left ventricle after the procedure.
Background
Coronary artery disease (CAD) remains a leading cause
of death and disability and results in a significant social
and economic burden to the health care system. Cur-
rently available options for treating CAD include life
style changes in conjunction with drug therapy, percuta-
neous coronary intervention (PCI) and coronary artery
bypass graft (CABG) surgery. It is estimated, however,
that 1-3% of patients presenting with diffuse CAD are
not candidates for conventional revascularization and
that 15-25% of patients undergoing CABG will have one
or more major target areas incompletely revascularized
due to diffuse coronary artery disease[1].
Incomplete revascularization is increasingly recognized
as an independent predictor of operative mortality[2],
particularly in the elderly[3]. Transmyocardial revascu-
larization (TMR) is an approved surgical procedure to
treat patients with diffuse coronary artery disease in
which 1 mm transmural laser channels are created in
ischemic myocardium which cannot be conventionally
revascularized. TMR can be performed either as a stand
alone procedure (sole therapy) in patients with medically
refractory angina who are not candidates for conven-
tional revascularization or in conjunction with CABG in
patients who would be incompletely revascularized by
CABG alone. Although sole therapy TMR has demon-
strated superiority over continued medical therapy in
randomized trials[3-8], its effectiveness at angina relief is
not 100%. Approximately 25% of patients treated with
sole therapy TMR do not experience a two class reduc-
tion in angina at one year[3,5].
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laser is hypothesized to provide a ‘fertile’ area for an
enhanced stem cell paracrine effect. To increase the
angiogenic response and associated clinical efficacy of
TMR, the potential synergy of combining TMR with a
cell-based therapy was investigated. Recently we
described our Bone Marrow Laser Revascularization
(BMLR) technique[9] in which a single device is used to
perform holmium:YAG TMR (PHOENIX™,C a r d i o G e n -
esis, Irvine, CA) and inject concentrated autologous
bone marrow derived stem cells. Now we describe our
mid term results regarding clinical status, cardiac events
and images findings in patients treated with the BMLR
technique.
Methods
Patient Selection
Between June 2007 and December 2009, nineteen conse-
cutive patients with diffuse coronary artery disease and
with maximal refractory medical treatment class III/IV
angina who were not candidates for PCI or CABG were
prospectively evaluated for Bone Marrow Laser Revascu-
larization (BMLR). Agreement by a cardiologist and two
cardiac surgeons on inoperability was required for inclu-
sion in this study. The Ethics Committee and Institu-
tional Review Board approved this prospective, single
arm open label study and informed consent was
obtained from each patient. Inclusion criteria included
age over 18 and left ventricle ejection fraction >25%
with documented left ventricular reversible ischemia
documented by echocardiography, magnetic resonance
imagining or nuclear tests. Exclusion criteria included
severe chronic obstructive pulmonary disease, unstable
angina requiring intravenous nitrates, myocardial infarc-
tion within two weeks of surgery, decompensated con-
gestive heart failure, refractory arrhythmias and bleeding
disorders.
Surgical Technique
Our technique has been previously described[9]. Briefly,
after the bone marrow aspiration the patient was reposi-
tioned supine with the left shoulder elevated and a lim-
ited anterior lateral left thoracotomy incision was
performed on a beating heart through the fifth inter-
space allowing exposure of the distal two-thirds of the
left ventricle for BMLR. No heparinization was required.
BMLR was performed using the PHOENIX combination
delivery system consisting of a 1 mm flexible optical
fiber (connected to a 20 watt pulsed holmium:yttrium-
aluminum-garnet (holmium:YAG) laser) along with a
needle injection system. A bolus of 150 mg of amiodar-
one was administered before starting the BMLR proce-
dure. An average of 20 laser channels (range 15-25)
were created in each patient. The three retractable
needles deployed after each channel and 1 mL of con-
centrated mononuclear cells were injected into the myo-
cardium around the channel.
All adverse events were recorded. Myocardial injury
was monitored postoperatively measuring creatinine
kinase (CKMB) and troponin. Efficacy endpoints
included blinded angina assessment, change in cardiac
medication usage and rates of cardiac hospital readmis-
sion following the procedure.
Follow-up
All patients were reviewed by a cardiac surgeon and by
a cardiologist. MRI and SPECT test were performed
before and 6-12 months after the procedure.
Statistics
Patient demographics and perioperative variables were
collected prospectively. Continuous variables are
expressed as mean ± standard deviation and categorical
data as proportions. Student’s T-test or the Mann-Whit-
ney U-test was used for continuous variables compari-
sons. Categorical variables were compared using chi-
square analysis. Patient follow-up was performed by
citation in hospital or by telephone. All statistical ana-
lyses were performed using SPSS statistical package 14.0
(SPSS Corp., Birmingham, AL, USA)
Results
Patient Characteristics
Nineteen patients (16 male: 3 female) with a mean age
of 65.2 ± 6.1 years (range 52-78) underwent BMLR.
Baseline clinical characteristics are described in Table 1.
Baseline Canadian Cardiovascular Class was Class IV in
seven patients and Class III in twelve patients. Fifteen
patients had prior PCI procedures (mean 3.3 interven-
tions; range: 1-7). Eight patients had previous CABG
procedures. Mean baseline ejection fraction was 54%
(range 30-65).
Safety Analyses
All nineteen patients enrolled in the trial underwent
successful BMLR without complications including no
surgical mortality and no perioperative arrhythmias.
Table 1 Baseline clinical characteristics of patients (n = 19)
n (%)
Hypertension 18 (94.7%)
Diabetes 11 (57.9%)
Dyslipemia 16 (84.2%)
Current smoking 4 (21%)
Peripheral vascular disease 4 (21%)
Lung disease 2 (10.5%)
Crhonic myocardial infarction 12 (63,2%)
Sinus rhythm 19 (100%)
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row aspiration. One diabetic patient developed a superfi-
cial wound infection in her inframammary incision three
weeks following surgery which healed uneventfully. Car-
diac enzymes were measured at 2, 6, and 18 hours fol-
lowing the procedure (Figure 1). Postoperatively median
length of stay in the intensive care unit was one day and
average total length of stay was 5.5 days.
Average follow-up was nineteen months (range: 2-
30 months). There was one late death 28 months post
procedure in a uncontrolled diabetic female due to heart
failure
Efficacy Analyses
Average follow-up was nineteen months and it was com-
plete in all nineteen patients. Average angina class was
significantly improved from baseline to follow up (3.4 ±
0.5 vs 1.7 ± 0.9; p < 0.001). All patients experienced a
two class reduction in angina with 50% (7/14) angina free
six months post procedure. Monthly cardiac medication
usage overall was significantly decreased (348 ± 118 vs.
201 ± 92; p = 0.001) with the number of sublingual
nitrates taken per month reduced (22.1 ± 30.4 vs. 1.4 ±
3.9; p < 0.001). Significant reduction in cardiac related
hospitalizations in the six months following treatment
with BMLR compared to the six months prior to study
enrollment (0.5 ± 0.8 vs 2.9 ± 2.3; p < 0.001)
Three patients received follow on cardiac catheteriza-
tion post BMLR due to advancing disease. Two were
successfully intervened in territories with new lesions,
the other could not receive further intervention.
Cell Counts
Mononuclear cells (MNCs) from the bone marrow aspi-
rate were harvested and concentrated intraoperatively.
Average time to complete the bone marrow aspiration
and concentrate the cells was 30 minutes. Table 2
demonstrates the mean number of total MNCs, CD34+
cells, and CD133+ cells before and after the
centrifugation.
Diagnostic Results
Follow up MRI was performed 6 months post proce-
dure. Average EF% at baseline was of 47% and average
EF% at follow-up was 50%. This is a 3% increase in EF%
after BMLR treatment. Dimensional measures of the left
ventricle were also documented, with no change in end
diastolic or end systolic volumes. Patients diagnosed
using SPECT did not show changes in fixed or variable
defects.
Discussion
We combined TMR with autologous bone marrow
derived stem cells injection in patients suffering angina
despite medical treatment and with diffuse coronary dis-
ease non-manageable with standard surgical options.
The procedure was feasible with no complications and it
resulted a clinical improvement in patients. There was
significant reduction in angina class, number of cardio-
vascular medication and cardiac related hospital
admissions.
Transmyocardial revascularization is an approved sur-
gical procedure to treat ‘no option’ patients with diffuse
coronary artery disease. In prospective randomized trials
sole therapy TMR has demonstrated a significant
improvement in angina and event free survival and a
reduction in cardiac related hospitalizations compared
to patients randomized to maximum medical therapy
alone[3,5-8]. Long term follow up of TMR as a primary
therapy shows an enduring benefit over time[4,10] and
5 year follow up of one prospective randomized trial
involving the sickest Canadian Cardiovascular Class IV
patients has shown improved survival in the TMR trea-
ted patients[4]. In a recent meta-analysis the superiority
of TMR versus maximal medical management at one
and 3-5 year follow-up with regard to two class angina
improvement has been confirmed[11]. The Society of
Thoracic Surgery and the International Society of Mini-
mally Invasive Cardiothoracic Surgeons (ISMICS) have
published practice guidelines giving sole therapy TMR a
Grade I recommendation with Level A evidence.
Although TMR’s superiority over medical therapy has
been demonstrated in randomized trials, in up to 25% of
patients treated with TMR, angina relief is not signifi-
cantly improved at one year and the percentage of
patients who become angina free is approximately 20%
[3,5]. In prospective series all patients significantly
improve in angina class through the period of follow up.
As a potential alternative to TMR, exogenously admi-
nistered biologic substances such as growth factors and
stem cells have been evaluated for the treatment of
medically-refractory angina. Direct intramyocardial
Figure 1 Troponin and CPKmb levels measured at 2, 6 and
18 hours after BMLR.
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endothelial growth factor and basis fibroblastic growth
factor have yielded angina improvement in inoperable
patients and may positively effect left ventricular func-
tion[12]. The use of intramyocardial injection of autolo-
gous bone marrow derived mononuclear cells such as
CD34+ and AC133+ stem cells has also yielded positive
efficacy signals with regard to angina improvement and
myocardial perfusion in patients with refractory ische-
mia[13,14].
TMR results in an up regulation of vascular endothe-
lial growth factor messenger RNA and an increased
expression of other angiogenic growth factors[15].
Hugh’s and colleagues[16] examined the neovasculariza-
tion response six months post-TMR in an ischemic por-
cine model and reported significant increases in vascular
density in lased regions. In addition they reported that
laser systems which create an injury (carbon dioxide
and Holium:YAG) improved myocardial blood flow and
contractile reserve in lased regions, whereas improve-
ments were not observed following a sham thoracotomy
or using a non injury producing lasers (eximer). When
mechanical TMR has been compared to laser TMR,
mechanical TMR resulted in no angiogenic response
suggesting that a threshold injury to an ischemic myo-
cardial region was needed to induce angiogenesis[17]. In
an evaluation of their cumulative studies, Hughes and
Lowe concluded that TMR induced neovascularization
in lased regions is likely due to an up regulation of the
angiogenic cascade secondary to an inflammatory
response after laser treatment. Bone Marrow Laser
Revascularization (BMLR) describes the delivery of auto-
logous bone marrow concentrate in conjunction with
TMR channels into targeted ischemic tissue. It is the
hypothesized that the delivery of bone marrow derived
stem cells into the order zone surrounding the channels
will significantly enhance the angiogenic response com-
pared to TMR alone. We have proved that this surgical
approach is safe, easily reproducible and it can be per-
formed in 60-90 minutes. We had no device related
complications, and only one procedurally related com-
plication - a surgical wound healing complication in a
severely diabetic patient. This despite a relatively high
risk patient series with diffuse coronary heart disease
and most with additional cardiovascular risk factors.
The procedure was performed in an average of 90 min-
utes with no significant operative events. It is the
hypothesized that the delivery of bone marrow derived
stem cells into the border zone surrounding the chan-
nels may significantly enhance the angiogenic response
and resulting clinical effect compared to TMR alone.
Utilizing TMR as a biomechanical trigger to enhance
the angiogenic cascade when combined with an adjunc-
tive biological therapy is supported by enhanced perfu-
sion and improved mechanical function when evaluated
in ischemic animal models[18]. Recent animal studies
provide insight into possible mechanisms of synergy
between TMR and biologic substances. Atluri and col-
leagues[19] demonstrated that the localized acute heal-
ing response to the laser injury includes an up
regulation of injured myocytes, platelet activation with
growth factor release from the thrombus that forms
within the laser channel, as well as the recruitment of
intrinsic myocardial stem cells. In addition, Patel and
colleagues[20] demonstrated enhanced stem cell reten-
tion when stem cells are injected into the border zone
of a laser channel suggesting the microenvironment cre-
ated by the laser-tissue interaction may be important for
stem cell retention in ischemic tissue. Finally, the small,
early clinical experience with TMR combined with stem
cell therapy has demonstrated its safety and feasibility
and the potential for improving outcomes[21,22]. Weh-
berg and colleagues recently demonstrated superior
angina relief and significant ejection fraction improve-
ment when sole therapy TMR was combined with plate-
let rich plasma compared to TMR alone. A randomize
trial comparing TMR versus BMLR is required to vali-
date this hypothesis.
This patient series demonstrated that the clinical ben-
efit was achieved without adverse events. The diagnos-
tics performed showed no change in the functional
performance of the left ventricle. These data support the
safety of and feasibility of the BMLR technique.
Although special methods as three dimensional micro-
vascular lectin angiogram [19] or the modified Clark
electrode[23] has been used in animals models it is
believed that conventional methods may not be sensitive
enough to identify subtle changes after stem cell injec-
tion[23]. The objective of this study was to evaluate the
safety and feasibility of the BMLR treatment while initi-
ally collecting effeicacy outcomes data. The MRI and
SPECT performed ruled out any adverse remodeling of
the left ventricle, but may not be ideal for identifying
the physiologic effect of the treatment.
Our preliminary results demonstrate the safety and
feasibility of combining TMR and the implantation of
Table 2 Bone marrow aspiration cell counts per milliliter before and after concentration (p < 0.05 in all cases)
Bone Marrow Aspiration Average Total MNC (10
6 /ml ± range) Average CD34+ (10
6 /ml ± range) Average CD133+ (10
6 /ml ± range)
Pre Concentrate (120cc) 27.9 (15.1 - 45.0) 0.16 (0.04 - 0.3) 0.11 (0.001 - 0.2)
Post Concentrate (20cc) 81.3 (43.7 - 156.8) 0.6 (0.1 - 1.4) 0.37 (0.001 - 0.1)
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cells, and delivering them through a single device. In
this prospective series, the magnitude of angina relief
demonstrated with BMLR was favorable when compared
to publish TMR as a stand-alone therapy. In addition,
the bone marrow concentration method (SmartPrep2,
Harvest Technologies, Plymouth, MA, USA) allowed
rapid and efficient concentration of bone marrow aspi-
rate in the operating room while obtaining high stem
cell counts with minimal manipulation of the autologous
material. In a recent meta-analysis[24] the mean number
of mononuclear cells concentrated using cumbersome
and time consuming chemical or filtering techniques
was 80 × 10
6/ml compared to 81.3 × 10
6/ml observed
with this technique. Our mean count of mononuclear
cells was 81.3 (43.7 - 156.8) × 10
6 per millilitre and we
obtained 20 cc of concentrated bone marrow mononuc-
lear cells which may be adequate to achieve the desired
clinical result.
Limitations of the study
This is prospective single arm open label study in 19
patients to assess the safety and feasibility of the BMLR
treatment. Longer follow up and randomized groups are
required to assess the potential synergy of TMR com-
bined with bone marrow derived stem cells. Cardiac
imaging to evaluate perfusion and function (cardiac MRI
and SPECT nuclear study) were included in this study.
Additional diagnostic techniques or methods may be
required to asses the physiological impact of the BMLR
treatment.
A randomized trial comparing TMR versus BMLR is
required to assess the superiority of adding stem cells to
the TMR procedure.
Conclusions
Cardiac surgeons are increasingly faced with a more
complex patient who has developed a pattern of diffuse
coronary artery disease who cannot be completely revas-
cularized by conventional techniques. The point of care
bone marrow aspirate centrifuge system provides a
straight forward method for intraoperative harvesting
and preparation of autologous stem cells. The combina-
tion delivery system provides for the efficient delivery of
TMR and concentrated cells in targeted ischemic myo-
cardium. This advanced treatment for inoperable CAD
is safe and feasible. Prospective, randomized, multi-cen-
ter trials are required to determine the degree of syner-
gistic effect.
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